What's new

Human medicines European public assessment report (EPAR): Tabrecta, capmatinib, Date of authorisation: 20/06/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Tabrecta, capmatinib, Date of authorisation: 20/06/2022, Revision: 3, Status: Authorised

Jun 19, 2025 - 12:25
 0
Human medicines European public assessment report (EPAR): Tabrecta, capmatinib, Date of authorisation: 20/06/2022, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Tabrecta, capmatinib, Date of authorisation: 20/06/2022, Revision: 3, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Rybrevant, amivantamab...

Next Article

Can the US power grid keep up with the AI data centre boom?

Related Posts

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 18, 2025  0

Agenda of the PRAC meeting 2-5 June 2025

Jun 2, 2025  0

Human medicines European public assessment report (EPAR): Xromi, hydroxycarbamide, Date of authorisation: 01/07/2019, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 17, 2025  0